Makers Laboratories DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023


0.86×	—	1.00×	0.94×
0.97×	−0.97×	1.07×	1.04×
−4.1%	−11.8%	−13.2%	−15.4%
0.69×	0.55×	0.57×	0.50×
1.35×	1.27×	1.67×	1.45×
−3.2%	—	−13.5%	−10.9%
−3.1%	—	−12.7%	−10.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

MAKERSL₹187.00

Makers Laboratories Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA JENBURPH KPL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOCMcap ₹111 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.94	1.00	—	0.86
Interest Burden (Pretax/EBIT) ×	1.04	1.07	-0.97	0.97
EBIT Margin %	-15.35	-13.19	-11.77	-4.12
Asset Turnover ×	0.50	0.57	0.55	0.69
Financial Leverage (Assets/Equity) ×	1.45	1.67	1.27	1.35
ROE (5-step product, year-end total equity) %	-10.87	-13.52	—	-3.18
ROE (owners' profit / average owners' equity) %	-10.91	-12.67	—	-3.11

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.